Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -753.60% is 58% below its 5-year average of -477.72%, around the middle of its 5-year range (-4132.24%–1235.55%).
38.50% above its 12-month average of -1225.28%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -660.78%.
NET PROFIT MARGIN
-753.60%
NET PROFIT MARGIN AVG TTM
-1225.28%
NET PROFIT MARGIN AVG 3Y
-488.26%
NET PROFIT MARGIN AVG 5Y
-477.72%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+38.50%
CURRENT VS 3Y AVG
-54.35%
CURRENT VS 5Y AVG
-57.75%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-289746.15%
vs the sector median at left
Stoke Therapeutics, Inc.
Market Cap
$1.57B
Net Profit Margin
-753.60%
TTM Avg
-1225.28%
3Y Avg
-488.26%
5Y Avg
-477.72%
Market Cap
$1.59B
Net Profit Margin
-140.43%
TTM Avg
-164.31%
3Y Avg
-442.76%
5Y Avg
-354.21%
Market Cap
$1.60B
Net Profit Margin
-1350.73%
TTM Avg
-1059.67%
3Y Avg
-1046.38%
5Y Avg
-742.65%
Market Cap
$1.54B
Net Profit Margin
-87.60%
TTM Avg
-755.85%
3Y Avg
-377.93%
5Y Avg
-1051.76%
Market Cap
$1.61B
Net Profit Margin
-579.10%
TTM Avg
-408.42%
3Y Avg
-273.23%
5Y Avg
-333.72%
Market Cap
$1.54B
Net Profit Margin
80.56%
TTM Avg
35.15%
3Y Avg
48.19%
5Y Avg
54.54%
Market Cap
$1.61B
Net Profit Margin
-24.51%
TTM Avg
-3392.63%
3Y Avg
-1004.26%
5Y Avg
-1004.26%
Market Cap
$1.62B
Net Profit Margin
-13.50%
TTM Avg
-22.64%
3Y Avg
-31.77%
5Y Avg
-40.07%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | $1.57B | -753.60% | -1225.28% | -488.26% | -477.72% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | -140.43% | -164.31% | -442.76% | -354.21% |
| uniQure N.V. (QURE)vs › | $1.60B | -1350.73% | -1059.67% | -1046.38% | -742.65% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -87.60% | -755.85% | -377.93% | -1051.76% |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | -579.10% | -408.42% | -273.23% | -333.72% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 80.56% | 35.15% | 48.19% | 54.54% |
| Septerna Inc (SEPN)vs › | $1.61B | -24.51% | -3392.63% | -1004.26% | -1004.26% |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 3.13% | 0.65% | -0.01% | 1.74% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | -13.50% | -22.64% | -31.77% | -40.07% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 10.82% | 2.93% | -1.36% | -5.99% |
Operating Margin
-11.2%
Net Profit Margin
-753.6%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -660.78% |
| 2026-03-31 | -802.75% |
| 2025-12-31 | -4132.24% |
| 2025-09-30 | -360.68% |
| 2025-06-30 | -169.96% |
| 2025-03-31 | 71.19% |
| 2024-12-31 | -46.35% |
| 2024-09-30 | -540.05% |
| 2024-06-30 | -531.88% |
| 2024-03-31 | -625.57% |
| 2023-12-31 | -962.10% |
| 2023-09-30 | -741.90% |
| 2023-06-30 | 1235.55% |
| 2023-03-31 | -437.60% |
| 2022-12-31 | -784.80% |
| 2022-09-30 | -898.83% |
| 2022-06-30 | -762.98% |
| 2022-03-31 | -821.63% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
